Dóchas Life Sciences’ Post

#OnlineFirst w/ #PMT #JPharmTechnol this week, Khanna & colleagues assess potential #druginteractions in patients w/ #chronickidneydisease https://lnkd.in/gTgMVjsC #medicationmanagement #pharmacists #pharmacy

NICE Approves Etrasimod for Ulcerative Colitis: A New Hope for Patients Aged 16 and Over The National Institute for Health and Care Excellence has endorsed the use of Etrasimod for ulcerative colitis patients who have not responded well to conventional treatments. Etrasimod, sold under the name Velsipity by Pfizer, has shown promising results in clinical trials and is a cost-effective option. The guidance includes a commercial arrangement with the NHS to offer discounts on the drug. NHS England and integrated care boards are required to ensure availability of Etrasimod within a specified timeframe. For more details please click the link! https://lnkd.in/d85SBxXY #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

FDA Approves Ocrevus Zunovo for 2 Forms of Multiple Sclerosis: The approval marks the first and only twice yearly, health care professional-administrated injection for both forms of multiple sclerosis (MS). #finance #pharmacy #lifesciences

"I have recently authored an article titled 'A Study of Severe Anaemia in Children in a Tertiary Health Care Institute,' which has been published in the Journal of Pharmaceutical and Clinical Trials and Practice (JPTCP). Below is the link to the article." https://lnkd.in/gXHqGkNb

Plexiform Neurofibromas Targeted by Mirdametinib as FDA Grants Priority Review SpringWorks Therapeutics has received FDA Priority Review for mirdametinib, an investigational MEK inhibitor for treating plexiform neurofibromas in adults and children, with a PDUFA action date set for February 28, 2025. If approved, it could be the first treatment for adults with NF1-PN and a leading therapy for pediatric patients. The New Drug Application and the European Medicines Agency submissions are based on positive Phase 2b ReNeu trial data, showing strong response rates, pain reduction, and improved quality of life. This marks a key milestone for SpringWorks Therapeutics in addressing a significant unmet medical need. For more details please click the link! https://lnkd.in/dkJa2QhA #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Treatment Access: PHARMAC Proposes Expanded Access to Urinary Tract Infections Treatment and New Epilepsy Medication Funding PHARMAC has opened a consultation to expand access to treatments for urinary tract infections and certain types of epilepsy, aiming to benefit over 2,900 New Zealanders in the first year. Alexandra Compton, Senior Therapeutic Group Manager at PHARMAC, noted that the proposals include community provision of fosfomycin for UTIs, which could reduce hospital-treated cases by 80%, and funding zonisamide for epilepsy. Supported by new government funding, this initiative seeks feedback from those affected, with the consultation open until August 1. If approved, these changes will enhance treatment access and reduce healthcare burdens in New Zealand. For more details please click the link! https://lnkd.in/gqTeCide #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Learn about the pivotal role of diversity in patient-centric research. Discover more at: https://lnkd.in/dWYCJKvv #PatientCentric #PatientCentricity #ClinicalTrials #DiversityInResearch #Octalsoft #Innovation #Efficiency #EclinicalSoftware #CRO #PharmaTech #Healthcare #HealthcareIndustry #ClinicalResearch #HealthcareSector #Pharma #Blogs #PharmaceuticalIndustry #ClinicalTrial #Blog #LifeSciences #HealthcareInnovation 

Over the past 3 decades, Phase 3 clinical trials have transformed multiple sclerosis treatment. These trials involve an incredible collaborative effort from MS patient volunteers, MS center staff, research organization personnel, pharmaceutical experts, and investigational review board members. As a Phase 3 investigator, I've had the privilege of contributing to the introduction of multiple groundbreaking medications for people with MS including Gilenya, Aubagio, Mayzent, Vumerity, Mavenclad, Lemtrada, and Ocrevus. I'm honored to be first author on the recently published final results of the Phase 3 EVOLVE-MS-1 study on diroximel fumarate (Vumerity) in the Multiple Sclerosis Journal. Thanks to all involved in the trial, especially the MS study participants. Thanks also to my co-authors including Mark Gudesblatt, Jiwon Oh and Tjalf Ziemssen. #Phase3 #MS #clinicaltrials #diroximelfumarate #Vumerity

Excited to share our latest research published in #CPT 📝! The randomized #AMBORA trial showed that medication errors are frequent in patients undergoing 💊 oral antitumor therapy and that an intensified clinical pharmacological/pharmaceutical care program can solve more than 85%. We're proud to have implemented this concept directly post-study within the AMBORA Competence and Consultation Center, providing real-world context for our research. A key finding 💡? Medication errors involving the oral antitumor drugs were twice as high in real-world settings compared to the controlled trial, emphasizing the importance of implementing such programs in clinical practice ✔! For more insights and error characteristics, check out the full article: https://lnkd.in/dm6XjbvW Mag.pharm. Lisa Cuba Pauline Dürr Frank Dörje, Prof. Dr.; MBA Prof. Dr. Martin F. Fromm #FAU #UKER #DKH

Gynica Healthcare, an Israeli pharmaceutical company, has initiated a clinical trial for a potential cure for endometriosis, a common and often debilitating condition affecting women. "This trial represents a significant step forward in our mission to revolutionize care and provide a better quality of life for the millions of women worldwide suffering from endometriosis." The trial marks a significant step forward in addressing the unmet medical needs of individuals suffering from endometriosis, offering hope for improved treatment options in the future. #pharma #endometriosis #clinicaltrials